CYTK – Cytokinetics, Incorporated
CYTK
$56.18Name : Cytokinetics, Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,826,061,824.00
EPSttm : -6.02
Cytokinetics, Incorporated
$56.18
CYTK — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.86
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
0.04
EPS Last/This Y
0.55
EPS This/Next Y
1.59
Price
56.24
Target Price
109.42
Analyst Recom
1.22
Performance Q
-25.73
Upside
-476.3%
Beta
0.49
Ticker: CYTK
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | CYTK | 62.79 | 0.15 | 0.01 | 81938 |
| 2026-10-13 | CYTK | 61.66 | 0.15 | 0.61 | 82561 |
| 2026-10-14 | CYTK | 63.49 | 0.15 | 0.06 | 82484 |
| 2026-10-15 | CYTK | 63.92 | 0.15 | 0.73 | 83236 |
| 2026-10-16 | CYTK | 61.97 | 0.14 | 2.85 | 82944 |
| 2026-10-19 | CYTK | 62.7 | 0.14 | 0.46 | 78632 |
| 2026-10-20 | CYTK | 63.89 | 0.14 | 0.03 | 79463 |
| 2026-10-21 | CYTK | 62.89 | 0.14 | 36.31 | 80265 |
| 2026-10-22 | CYTK | 62.28 | 0.17 | 0.22 | 82010 |
| 2026-10-23 | CYTK | 61.2 | 0.17 | 2.87 | 82004 |
| 2026-10-26 | CYTK | 60.77 | 0.17 | 0.08 | 81960 |
| 2026-10-27 | CYTK | 61.65 | 0.17 | 0.02 | 82063 |
| 2026-10-28 | CYTK | 61.3 | 0.17 | 0.03 | 82525 |
| 2026-10-29 | CYTK | 63.34 | 0.17 | 0.07 | 82267 |
| 2026-10-30 | CYTK | 63.01 | 0.17 | 0.69 | 82343 |
| 2026-11-02 | CYTK | 62.05 | 0.17 | 0.10 | 82351 |
| 2026-11-03 | CYTK | 62.59 | 0.17 | 0.00 | 82355 |
| 2026-11-04 | CYTK | 64.32 | 0.17 | 0.20 | 82382 |
| 2026-11-05 | CYTK | 55.71 | 0.17 | 4.74 | 82472 |
| 2026-11-06 | CYTK | 53.69 | 0.18 | 0.73 | 83566 |
| 2026-11-09 | CYTK | 55.12 | 0.18 | 0.22 | 83583 |
| 2026-11-10 | CYTK | 56.21 | 0.18 | 0.20 | 86335 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | CYTK | 62.79 | 7.2 | - | -5.94 |
| 2026-10-13 | CYTK | 61.66 | 7.3 | - | -5.94 |
| 2026-10-14 | CYTK | 63.44 | 7.3 | - | -5.94 |
| 2026-10-15 | CYTK | 63.94 | 7.3 | - | -5.94 |
| 2026-10-16 | CYTK | 61.97 | 7.3 | - | -5.94 |
| 2026-10-19 | CYTK | 62.68 | 7.3 | - | -5.94 |
| 2026-10-20 | CYTK | 62.68 | 7.3 | - | -5.94 |
| 2026-10-21 | CYTK | 63.95 | 8.3 | - | -5.88 |
| 2026-10-22 | CYTK | 62.31 | 8.4 | - | -5.87 |
| 2026-10-23 | CYTK | 61.22 | 8.4 | - | -5.87 |
| 2026-10-26 | CYTK | 60.75 | 8.5 | - | -5.87 |
| 2026-10-27 | CYTK | 61.66 | 8.8 | - | -5.88 |
| 2026-10-28 | CYTK | 61.32 | 8.8 | - | -5.88 |
| 2026-10-29 | CYTK | 63.32 | 8.8 | - | -5.88 |
| 2026-10-30 | CYTK | 63.03 | 8.8 | - | -5.88 |
| 2026-11-02 | CYTK | 62.12 | 8.8 | - | -5.88 |
| 2026-11-03 | CYTK | 62.35 | 8.8 | - | -5.88 |
| 2026-11-04 | CYTK | 64.42 | 8.8 | - | -5.88 |
| 2026-11-05 | CYTK | 55.89 | 8.8 | - | -5.88 |
| 2026-11-06 | CYTK | 53.69 | 7.4 | - | -5.88 |
| 2026-11-09 | CYTK | 55.13 | 7.4 | - | -5.88 |
| 2026-11-10 | CYTK | 56.24 | 6.0 | - | -5.99 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | CYTK | -8.20 | 10.94 | 14.41 |
| 2026-10-13 | CYTK | -8.33 | 10.94 | 14.41 |
| 2026-10-14 | CYTK | -8.33 | 10.94 | 14.41 |
| 2026-10-15 | CYTK | -8.33 | 10.94 | 14.41 |
| 2026-10-16 | CYTK | -8.07 | 10.94 | 14.41 |
| 2026-10-19 | CYTK | -8.07 | 11.09 | 14.41 |
| 2026-10-20 | CYTK | -8.07 | 11.09 | 14.41 |
| 2026-10-21 | CYTK | -8.13 | 11.09 | 14.41 |
| 2026-10-22 | CYTK | -8.07 | 11.09 | 14.41 |
| 2026-10-23 | CYTK | -8.07 | 11.09 | 14.41 |
| 2026-10-26 | CYTK | -8.07 | 10.68 | 14.41 |
| 2026-10-27 | CYTK | -8.07 | 10.68 | 13.89 |
| 2026-10-28 | CYTK | -8.07 | 10.68 | 13.89 |
| 2026-10-29 | CYTK | -8.07 | 10.68 | 13.89 |
| 2026-10-30 | CYTK | -7.94 | 10.68 | 13.89 |
| 2026-11-02 | CYTK | -7.68 | 10.61 | 13.89 |
| 2026-11-03 | CYTK | -7.81 | 10.61 | 13.89 |
| 2026-11-05 | CYTK | -7.60 | 10.61 | 13.89 |
| 2026-11-06 | CYTK | -6.48 | 10.61 | 13.89 |
| 2026-11-09 | CYTK | -6.47 | 9.82 | 13.86 |
| 2026-11-10 | CYTK | -6.47 | 9.82 | 13.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-1.37
Avg. EPS Est. Current Quarter
-1.41
Avg. EPS Est. Next Quarter
-1.33
Insider Transactions
-6.47
Institutional Transactions
9.82
Beta
0.49
Average Sales Estimate Current Quarter
62
Average Sales Estimate Next Quarter
69
Fair Value
Quality Score
15
Growth Score
53
Sentiment Score
5
Actual DrawDown %
49
Max Drawdown 5-Year %
-72.4
Target Price
109.42
P/E
Forward P/E
PEG
P/S
69.08
P/B
P/Free Cash Flow
EPS
-6.04
Average EPS Est. Cur. Y
-5.99
EPS Next Y. (Est.)
-4.4
Target Price Estimates Raised
1
Target Price Estimates Lowered
1
Profit Margin
-686.63
Relative Volume
1.19
Return on Equity vs Sector %
215.9
Return on Equity vs Industry %
235.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.05
EBIT Estimation
◆
CYTK
Healthcare
$56.18
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
21/25
Volume
1/15
Valuation
12/20
TP/AR
2/10
Options
8/10
RSI
35.7
Range 1M
15.4%
Sup Dist
4.1%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
6/25
Growth
20/30
Estimates
1/20
Inst/Vol
7/15
Options
8/10
EPS Yr
8.6%
EPS NY
27.8%
52W%
5.3%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+94.8% upside
Quality
7/30
Valuation
15/30
Growth
14/25
Stability
9/10
LT Trend
1/5
Upside
+94.8%
Quality
15
Click a card to see score breakdown
Full Analysis →
CYTK — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 673
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK
Latest News
—
Caricamento notizie per CYTK…
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading